Literature DB >> 11532383

Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials.

A Aleman1, R S Kahn.   

Abstract

Atypical antipsychotics have been hypothesized to be more effective than classical antipsychotics in the treatment of hostility and aggression, due to their characteristic pharmacological profile, involving serotonergic as well as dopaminergic systems. In the present quantitative review the published evidence regarding the effects of risperidone on hostility and aggression in schizophrenia is evaluated. Meta-analysis of seven controlled trials revealed significant differences between risperidone and classical antipsychotics and between risperidone and placebo, although the effect size was small. Additional analyses in which only methodological rigorous studies were included showed highly significant differences (risperidone versus classical antipsychotics) and the effect size approached the 'medium' range. We conclude that risperidone is superior to classical antipsychotics and placebo in the treatment of hostility and aggression in schizophrenia. Neuropharmacological mechanisms that might account for this effect are discussed, and directions for future research are outlined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532383     DOI: 10.1016/s0924-977x(01)00097-9

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

Review 1.  Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies.

Authors:  Lydia Krabbendam; André Aleman
Journal:  Psychopharmacology (Berl)       Date:  2003-01-24       Impact factor: 4.530

Review 2.  Neuropsychiatry of aggression.

Authors:  Scott D Lane; Kimberly L Kjome; F Gerard Moeller
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 3.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

Review 4.  Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.

Authors:  Margo D M Faay; Pál Czobor; Iris E C Sommer
Journal:  Neuropsychopharmacology       Date:  2018-07-23       Impact factor: 7.853

Review 5.  [Psychopharmacological treatment in the pre-clinical emergency medicine].

Authors:  F-G Pajonk; B Fleiter
Journal:  Anaesthesist       Date:  2003-07-10       Impact factor: 1.041

6.  Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.

Authors:  Y Barak; I Mirecki; H Y Knobler; Z Natan; D Aizenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-02-04       Impact factor: 4.530

7.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 8.  From Clozapine to Cognitive Remediation.

Authors:  Jason Quinn; Nathan J Kolla
Journal:  Can J Psychiatry       Date:  2016-07-10       Impact factor: 4.356

9.  Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.

Authors:  G Fond; L Boyer; M Favez; L Brunel; B Aouizerate; F Berna; D Capdevielle; I Chereau; J M Dorey; C Dubertret; C Faget; F Gabayet; H Laouamri; C Lancon; Y Le Strat; D Misdrahi; R Rey; C Passerieux; A Schandrin; F Schurhoff; A M Tronche; M Urbach; P Vidalhet; P M Llorca; A Pelissolo
Journal:  Psychopharmacology (Berl)       Date:  2015-12-03       Impact factor: 4.530

Review 10.  Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Mohsin Hussein; Uzair Ahmed; Faiz-Ur Rehman; Krista Miramontes; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.